

Fig 1 Combination therapy targeting CDK4/6 (palbociclib) as well as PI3K/mTOR (voxtalisib) significantly reduced tumor growth and was well-tolerated in un-pretreated (HT96) and heavily pre-treated (TT2-77) OS PDXs. **(A)** HT96 and **(B)** TT2-77 PDXs were treated with vehicle, palbociclib (50mg/kg), voxtalisib (50mg/kg), and combination of palbociclib (50mg/kg) + voxtalisib (50mg/kg) daily. Tumor growth (mean +/- SEM) was significantly reduced in single-agent groups compared to vehicle. Two-way ANOVA; Holm-Sidak's Multiple Comparison Test (n≤ 8/group) *** *p*<0.05 Combination vs Vehicle, **p*<0.05 Voxtalisib vs Vehicle, * *p*<0.05 Palbociclib vs Vehicle, # *p*<0.05 Single agents (Palbociclib and Voxtalisib) vs Combination.**